0%
Print report
Variant interpretation report

ASXL1 c.3184C>T, p.Pro1062Ser

NM_015338.5:c.3184C>T NP_056153.2:p.(Pro1062Ser) Missense · exon 13 View identifiers
Classification
Uncertain significance

Variant description:

The ASXL1 NM_015338.5:c.3184C>T (NP_056153.2:p.(Pro1062Ser)) missense variant has previously been reported in somatic cancers (COSMIC; COSV60106723, n = 2 times). Based on available guidelines, this variant is considered to be a Variant of Uncertain Significance (VUS).

Five-step scale from benign to pathogenic. This variant is uncertain. Select a step to read what it means.

Uncertain.The recorded classification is uncertain significance.

In plain language

Gene-level background from the recorded interpretation.

About ASXL1

ASXL1 encodes a chromatin-binding protein of the Polycomb group that helps regulate gene expression by recruiting repressive complexes (such as PRC2) to chromatin and modifying histone marks. Germline mutations in ASXL1 cause Bohring-Opitz syndrome, a developmental disorder with distinctive craniofacial abnormalities. Somatic loss-of-function mutations in ASXL1 are common in blood cancers, including myelodysplastic syndromes, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia, where the gene acts as a tumor suppressor. Loss of ASXL1 function disrupts normal repression of target genes, contributing to leukemogenesis.

LYFE Sciences is an AI system, and it can make mistakes. Criteria may be applied incorrectly, sources may be misread, and a confident-looking classification can still be wrong. Double-check every criterion and its underlying evidence before relying on any call.
01The reasoning

How it was classified

The recorded framework is Generic ACMG/AMP 2015 with ClinGen SVI recommendations. The criteria and strengths shown below come from the saved assessment; this page does not recalculate the classification.

Recorded applied criteria

The applied criteria and their strengths are shown as assessed under the stated framework.

Pathogenic evidence criteria: 1 Benign evidence criteria: 1
Pathogenic criteria applied · 1
PM2Moderate
PM2 · moderate

Met at Moderate: gnomAD v4.1 AF is 1.61073e-05, below the 0.0001 generic PM2 cutoff, with 0 homozygotes.

Benign criteria applied · 1
BP4Supporting
BP4 · supporting

Met at supporting: missense REVEL score 0.018 meets the BP4 threshold of <= 0.29.

Recorded classification: Uncertain significance

VUS: PM2 (moderate) and BP4 (supporting) do not satisfy any generic ACMG pathogenic, likely pathogenic, likely benign, or benign combination rule.

02The sources

Evidence at a glance

Evidence summaries and captured source records, where available. Missing entries should not be interpreted as negative findings.

gnomAD v4.1
gnomAD v2.1
Population frequency
26 / 1,614,170 alleles

gnomAD v4.1: 26 / 1,614,170 alleles. Recorded AF 1.61073e-05. Recorded homozygote count 0.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.19324e-05; MAF= 0.00119%, 3/251416 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 0.000163026; MAF= 0.01630%, 1/6134 alleles, homozygotes = 0); grpmax FAF= 2.92e-06.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

No screenshot for this evidence
REVEL score
0.018 recorded score

Recorded REVEL score: 0.018. Refer to the recorded PP3/BP4 rationale for interpretation.

ClinVar submissions
1 reported laboratory submissions

1 Uncertain significance. ClinVar API review status: criteria provided, single submitter.

Context only ClinVar ↗
Functional evidence
Statement recorded

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ASXL1, a tumor suppressor and epigenetic regulator, is inactivated by mutation in various cancer types, most frequently in myeloid malignancies.

No listed criterion applied OncoKB ↗
COSMIC
Cancer Hotspots
Somatic evidence
2 recorded samples

This variant has previously been reported in somatic cancers (COSMIC; COSV60106723, n = 2 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.

For specialists

Technical detail

ACMG/AMP criteria under Generic ACMG/AMP 2015 with ClinGen SVI recommendations, with the data and sources behind each one.

28 criteria with recorded statuses: 2 met · 10 not met · 11 not assessed · 5 not applicable. Open any row for the full reasoning, the rule and the evidence behind it.

Met Not met Not assessed Not applicable

The evaluated codon/residue/domain criteria provide no positive ACMG/AMP evidence: PS1 and PM5 lack pathogenic same-residue comparators, PM1 lacks a qualifying hotspot or domain, and PP2 and BP1 remain unassessed because their gene-level requirements are not established by citable case evidence.

No VCEP covers ASXL1; generic ACMG/AMP 2015 rules govern.

PS4 and PP4 cannot be assessed because the case evidence contains neither a variant-specific affected phenotype nor the required prevalence or phenotype-specificity data.

PP5 and BP6 are not triggered because ClinVar has only an exact-match single-submitter Uncertain significance record with no expert-panel classification.

COSMIC somatic occurrence does not establish BP5 without a disease case having an independently established alternate molecular basis.

The variant is missense, so only the generic REVEL path applies to PP3/BP4.

REVEL 0.018 meets the BP4 supporting threshold and does not meet the PP3 supporting threshold; the SpliceAI and BayesDel results are not used for these criteria.

Met · 2

PM2 ModerateACMG_2015Met at Moderate: gnomAD v4.1 AF is 1.61073e-05, below the 0.0001 generic PM2 cutoff, with 0 homozygotes. Details ▾Hide ▴
Reasoning

PM2 is met at the required ACMG/AMP 2015 Moderate strength. The variant is present only at an extremely low frequency in the default all-comers gnomAD datasets: AF 1.19324e-05 (3/251416 alleles) in gnomAD v2.1 and AF 1.61073e-05 (26/1614170 alleles) in gnomAD v4.1, both at or below the supplied generic cutoff of 0.0001, with 0 homozygotes in each dataset. No VCEP-specific non-cancer or exome-only population source is specified, so the all-comers entries are the governing default.

Rule
Absent from controls (or at extremely low frequency if recessive) in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 exome data: AF 1.19324e-05 (3/251416 alleles), MAF 0.00119%, homozygotes 0, grpmax FAF 2.92e-06.
  • gnomAD v4.1 exome data: AF 1.61073e-05 (26/1614170 alleles), MAF 0.00161%, homozygotes 0, grpmax FAF 1.533e-05.
  • Generic ACMG/AMP default supplied for this case: PM2 <= 0.0001 (0.01%) qualifies as extremely low frequency.
Sources
BP4 SupportingACMGMet at supporting: missense REVEL score 0.018 meets the BP4 threshold of <= 0.29. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, p.(Pro1062Ser), so the governing generic rule selects the REVEL path only; the SpliceAI score is not used for BP4. The REVEL score is 0.018, which is at or below the BP4 supporting cutoff of <= 0.29. Therefore BP4 is met at supporting strength. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... REVEL (missense in-silico): BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup: ASXL1 NM_015338.5:c.3184C>T, p.(Pro1062Ser), REVEL 0.018.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): BP4 supporting cutoff <= 0.29.
  • The variant is an exonic missense substitution; under the generic rule, REVEL is the sole applicable computational path, so the SpliceAI max delta 0.006 is not double-counted or substituted into BP4.
Sources
revel

Not met · 10 · evaluated, threshold not reached

PS1 ACMG_2015Not met: p.Pro1062Ser has no documented previously established pathogenic same-amino-acid change in the available evidence. Details ▾Hide ▴
Reasoning

The variant is NP_056153.2:p.(Pro1062Ser). The case evidence identifies only a ClinVar single-submitter uncertain-significance record for the exact variant and provides no previously established pathogenic variant producing the same amino-acid change. The available evidence therefore does not satisfy PS1.

Rule
Same amino acid change as a previously established pathogenic variant regardless of nucleotide change. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • ClinVar variation 4702721, NM_015338.6(ASXL1):c.3184C>T (p.Pro1062Ser): classification uncertain significance, criteria provided, single submitter; no pathogenic same-amino-acid comparator is recorded in the case evidence.
Sources
PM1 ACMG_2015Not met: Cancer Hotspots found no statistically significant hotspot for ASXL1 P1062, and no qualifying critical-domain evidence is available. Details ▾Hide ▴
Reasoning

The variant is p.Pro1062Ser in ASXL1. The case has no VCEP domain table or approved critical-domain specification, Cancer Hotspots returned no statistically significant hotspot for ASXL1 P1062, and COSMIC reports the exact variant only twice in somatic cancers without establishing a mutational hotspot. The available evidence does not establish that residue 1062 lies in a mutational hotspot or critical, well-established functional domain without benign variation.

Rule
Located in a mutational hot spot and/or critical and well-established functional domain (e.g. active site of an enzyme) without benign variation.
Evidence considered
  • Cancer Hotspots query ASXL1 P1062: no result; evidence sentence states that the variant does not lie in a statistically significant hotspot.
  • COSMIC COSV60106723: the exact variant was reported in somatic cancers 2 times, which does not by itself establish a mutational hotspot or critical functional domain.
  • vcep_materials.json: no CSPEC/VCEP materials and domain_tables is empty for ASXL1.
  • (cited as evidence_refs, but not a source_registry key: vcep_materials)
Sources
PM5 ACMG_2015Not met: the PM5 search contains zero same-residue candidates, and no different pathogenic missense change at Pro1062 is documented. Details ▾Hide ▴
Reasoning

The variant is p.Pro1062Ser. The case evidence contains no different missense variant at Pro1062 that has been determined to be pathogenic; the exact ClinVar record is uncertain significance and the PM5 candidate file contains zero same-residue candidates. Therefore PM5 is not met.

Rule
Novel missense change at an amino acid residue where a different missense change determined to be pathogenic has been seen before. ... Caveat: Beware of changes that impact splicing rather than at the amino acid/protein level.
Evidence considered
  • pm5_candidates.json: residue Pro1062, total_candidates_seen 0, same_residue_candidates 0, and no harvested comparator variants.
  • ClinVar variation 4702721: the exact p.Pro1062Ser variant is classified as uncertain significance, not pathogenic.
Sources
pm5_candidatesclinvar ↗
PP3 ACMGNot met: missense REVEL score 0.018 is below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, p.(Pro1062Ser), so the governing generic rule selects the REVEL path only; SpliceAI and BayesDel are not used for PP3 in this situation. The REVEL score is 0.018, below the PP3 supporting cutoff of >= 0.644, so PP3 is not met.

Rule
Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... REVEL (missense in-silico): PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup: ASXL1 NM_015338.5:c.3184C>T, p.(Pro1062Ser), REVEL 0.018.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): PP3 supporting cutoff >= 0.644.
  • The variant is an exonic missense substitution; under the generic rule, REVEL is the sole applicable computational path and the SpliceAI score is not counted for PP3.
Sources
revel
PP5 ACMG_2015Not met: ClinVar reports Uncertain significance from one non-expert submitter, not an exact-variant expert-panel Pathogenic or Likely pathogenic classification. Details ▾Hide ▴
Reasoning

The exact variant is listed in ClinVar as Uncertain significance with criteria provided by a single submitter and no expert-panel submission. This is not an exact-variant ClinVar expert-panel Pathogenic or Likely pathogenic classification, so PP5 is not met under the specified generic rule.

Rule
PP5: Reputable source recently reports variant as pathogenic, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 4702721 exactly matches ASXL1 c.3184C>T (p.Pro1062Ser) and reports Uncertain significance, criteria provided, single submitter, with zero expert-panel submissions.
  • The ordinary single-submitter ClinVar record cannot trigger PP5; no exact-variant ClinVar expert-panel Pathogenic or Likely pathogenic classification is present.
Sources
BA1 ACMG_2015Not met: grpmax FAF is 1.533e-05 in gnomAD v4.1, far below the 0.05 BA1 threshold. Details ▾Hide ▴
Reasoning

BA1 is not met. Under the generic default, BA1 requires an allele frequency of at least 0.05. The required filtering metric, grpmax FAF, is 2.92e-06 in gnomAD v2.1 and 1.533e-05 in gnomAD v4.1, both far below 0.05. The highest observed subpopulation point estimate in gnomAD v2.1 is 0.000163026 (1/6134 alleles), and in gnomAD v4.1 is 2.20334e-05 (26/1180026 alleles); neither supports BA1, and the applicable population sample sizes exceed 2000 observed alleles. No VCEP-specific non-cancer or exome-only source requirement is present, so the default all-comers gnomAD entries were used.

Rule
Allele frequency is above 5% in Exome Sequencing Project, 1000 Genomes or Exome Aggregation Consortium.
Evidence considered
  • gnomAD v2.1 exome data for ASXL1 NM_015338.5:c.3184C>T: total AF 1.19324e-05 (3/251416 alleles), homozygotes 0, grpmax FAF 2.92e-06; highest subpopulation point estimate 0.000163026 in Remaining individuals (1/6134 alleles).
  • gnomAD v4.1 exome data for ASXL1 NM_015338.5:c.3184C>T: total AF 1.61073e-05 (26/1614170 alleles), homozygotes 0, grpmax FAF 1.533e-05; highest subpopulation point estimate 2.20334e-05 in European non-Finnish individuals (26/1180026 alleles).
  • Generic ACMG/AMP default supplied for this case: BA1 >= 0.05; the filtering allele frequency is the grpmax FAF rather than the popmax point estimate.
Sources
BS1 ACMG_2015Not met: the highest applicable grpmax FAF is 1.533e-05, far below the 0.01 generic BS1 threshold. Details ▾Hide ▴
Reasoning

BS1 is not met on the available population data. The generic default threshold supplied for BS1 is 0.01, while the required filtering metric is grpmax FAF: 2.92e-06 in gnomAD v2.1 and 1.533e-05 in gnomAD v4.1. Both are far below 0.01, so the allele frequency is not greater than expected for the disorder on this evidence. The highest observed subpopulation point estimates do not override the FAF requirement. No disease-specific prevalence, penetrance, allelic heterogeneity, or maximum-credible-allele-frequency calculation is needed to reject this low-frequency BS1 path, and no VCEP-specific population source is present.

Rule
Allele frequency is greater than expected for disorder.
Evidence considered
  • gnomAD v2.1 exome data: grpmax FAF 2.92e-06; total AF 1.19324e-05 from 3/251416 alleles, with 0 homozygotes.
  • gnomAD v4.1 exome data: grpmax FAF 1.533e-05; total AF 1.61073e-05 from 26/1614170 alleles, with 0 homozygotes.
  • Generic ACMG/AMP default supplied for this case: BS1 >= 0.01; BS1 is defined by frequency being greater than expected for the disorder, with prevalence, penetrance, and allelic heterogeneity considered before using the default.
Sources
BS2 ACMG_2015Not met: gnomAD reports 0 homozygotes, with no documented healthy adult individual carrying the disease-relevant genotype. Details ▾Hide ▴
Reasoning

BS2 is not met. gnomAD reports 0 homozygotes for this variant in both v2.1 and v4.1, and the available population records do not identify a healthy adult carrier with the disease-relevant genotype or establish that the individual was unaffected at the expected disease age. Therefore there is no observed healthy-adult individual satisfying the generic BS2 definition.

Rule
Observed in a healthy adult individual for a recessive (homozygous), dominant (heterozygous), or X-linked (hemizygous) disorder, with full penetrance expected at an early age.
Evidence considered
  • gnomAD v2.1: 3/251416 total alleles and 0 homozygotes; population-level data do not provide healthy-adult clinical status.
  • gnomAD v4.1: 26/1614170 total alleles and 0 homozygotes; population-level data do not provide healthy-adult clinical status.
Sources
BP5 ACMG_2015Not met: COSMIC records two somatic cancer occurrences but provides no disease case with an independently established alternate molecular basis. Details ▾Hide ▴
Reasoning

COSMIC reports the variant twice in somatic cancers, but this is somatic cancer catalog information and does not document the variant in a disease case with an alternate molecular basis. No such alternate molecular diagnosis is supplied, so BP5 is not met.

Rule
BP5: Variant found in a case with an alternate molecular basis for disease.
Evidence considered
  • COSMIC records ASXL1 c.3184C>T as COSV60106723 with a somatic count of 2.
  • The COSMIC record does not establish that the variant was found in a germline disease case with an alternate molecular basis, and no alternate molecular diagnosis is documented in the case evidence.
Still missing
  • A documented disease case with an independently established alternate molecular basis is required.
Sources
BP6 ACMG_2015Not met: ClinVar reports Uncertain significance from one non-expert submitter, not an exact-variant expert-panel Benign or Likely benign classification. Details ▾Hide ▴
Reasoning

The exact variant is listed in ClinVar as Uncertain significance with criteria provided by a single submitter and no expert-panel submission. This is not an exact-variant ClinVar expert-panel Benign or Likely benign classification, so BP6 is not met under the specified generic rule.

Rule
BP6: Reputable source recently reports variant as benign, but the evidence is not available to the laboratory to perform an independent evaluation.
Evidence considered
  • ClinVar variation 4702721 exactly matches ASXL1 c.3184C>T (p.Pro1062Ser) and reports Uncertain significance, criteria provided, single submitter, with zero expert-panel submissions.
  • The ordinary single-submitter ClinVar record cannot trigger BP6; no exact-variant ClinVar expert-panel Benign or Likely benign classification is present.
Sources

Not assessed · 11 · no assessment recorded

PS2 ACMG_2015Not assessed: no affected-proband, confirmed maternity and paternity, or family-history evidence is documented for this variant. Details ▾Hide ▴
Reasoning

No case-specific evidence documents that the variant is de novo in an affected proband, that both maternity and paternity were confirmed, or that there is no family history. The available records provide variant normalization and population/ClinVar information but no proband or parental testing results.

Rule
De novo (both maternity and paternity confirmed) in a patient with the disease and no family history.
Evidence considered
  • The available case records contain no documented proband phenotype, family history, or parental testing results establishing a de novo event.
  • Variant normalization, ClinVar, population-frequency, and predictor records do not establish PS2.
Still missing
  • Affected-proband clinical diagnosis and family-history information.
  • Variant testing results for the proband and both biological parents, with confirmed maternity and paternity.
PS3 ACMG_2015Not assessed: no validated in vitro or in vivo assay of p.Pro1062Ser with documented controls or biological functional readout is available. Details ▾Hide ▴
Reasoning

No validated, reproducible in vitro or in vivo functional study of NM_015338.5:c.3184C>T (NP_056153.2:p.Pro1062Ser) is present in the available case evidence. Computational predictions and database annotations do not satisfy the PS3 definition, and no assay controls, biological readout, or clinical-laboratory validation is documented; therefore PS3 cannot be assessed rather than being met or not_met.

Rule
Well-established in vitro or in vivo functional studies supportive of a damaging effect on the gene or gene product.
Evidence considered
  • The consolidated case evidence contains no exact-variant functional assay report for NM_015338.5:c.3184C>T (NP_056153.2:p.Pro1062Ser).
  • Available computational predictions and database annotations are not direct functional studies and were not used to assign PS3.
Still missing
  • A validated, reproducible in vitro or in vivo assay directly testing p.Pro1062Ser is needed, with appropriate wild-type, damaging, and neutral controls and a biologically relevant readout.
PS4 ACMG_2015Not assessed: no affected/control counts or variant-specific disease case observation were available to evaluate increased prevalence or calculate an odds ratio. Details ▾Hide ▴
Reasoning

No affected-patient cohort, unaffected-control cohort, or case-control counts for NM_015338.5:c.3184C>T (ASXL1 p.Pro1062Ser) were identified. Therefore an odds ratio and 95% confidence interval cannot be calculated, and the available gnomAD population frequency alone does not establish the required increased prevalence in affected individuals. The literature_pass.json packet has no PS4-classified papers, and no variant-specific case observation with a disease phenotype is available for the Richards 2015 Note 2 exception.

Rule
PS4: The prevalence of the variant in affected individuals is significantly increased compared to the prevalence in controls. ... Note 1: Relative risk (RR) or odds ratio (OR), as obtained from case-control studies, is >5.0 and the confidence interval around the estimate of RR or OR does not include 1.0.
Evidence considered
  • gnomAD v4.1 reports 26/1,614,170 total alleles (AF 1.61073e-05) and 26/1,180,026 European non-Finnish alleles (AF 2.20334e-05), but these are population data and provide no affected-patient prevalence or matched case-control comparison.
  • literature_pass.json contains zero ai_classified_papers and no PS4 criterion entry; no paper in the packet supplies affected/control counts, an odds ratio, or a variant-specific disease case observation.
  • No OR or 95% CI was computed because no case and control counts or case frequency were available.
Still missing
  • A variant-specific affected cohort and matched unaffected or population control data are required.
  • A documented disease phenotype and case observation are required if relying on the Richards 2015 PS4 Note 2 exception.
Sources
PM6 ACMG_2015Not assessed: no assumed-de novo observation in an affected patient or parental-testing information is documented. Details ▾Hide ▴
Reasoning

No case-specific evidence documents an assumed de novo variant in an affected patient. There are no reported parental testing results, maternity/paternity information, or proband clinical data from which PM6 could be evaluated.

Rule
Assumed de novo, but without confirmation of paternity and maternity.
Evidence considered
  • The available case records contain no documented affected-patient observation linked to this variant as assumed de novo.
  • No parental testing, maternity/paternity, or family-history data are available to distinguish PM6 from PS2.
Still missing
  • Affected-patient clinical phenotype and family-history information.
  • Evidence that the variant was observed as assumed de novo, including available but unconfirmed parental testing details.
PP1 ACMG_2015Not assessed: no affected-relative genotypes, phenotype data, pedigree, or informative meioses are documented for co-segregation. Details ▾Hide ▴
Reasoning

No pedigree, affected-relative genotypes, phenotype assessments, or informative meioses are documented. Therefore, co-segregation with disease in multiple affected family members cannot be evaluated at supporting strength or any stronger 2015 PP1 level.

Rule
Co-segregation with disease in multiple affected family members in a gene definitively known to cause the disease.
Evidence considered
  • The available case records contain no family pedigree, affected-relative testing, segregation observations, or meiosis count.
  • No source in the case records provides variant-specific co-segregation evidence.
Still missing
  • Pedigree identifying affected relatives and their phenotype status.
  • Variant genotypes for affected relatives and informative family meioses sufficient to assess co-segregation.
PP2 ACMG_2015Not assessed: the available evidence does not establish both low benign missense variation and a common disease-causing missense mechanism for ASXL1. Details ▾Hide ▴
Reasoning

The available case evidence does not provide a citable gene-level analysis establishing both required PP2 components for ASXL1: a low rate of benign missense variation and missense variants as a common disease mechanism. OncoKB describes ASXL1 as a tumor suppressor and epigenetic regulator inactivated in cancers, but that gene-level somatic context does not establish the ACMG germline PP2 rule. A validated gene-level missense-spectrum source is required.

Rule
Missense variant in a gene that has a low rate of benign missense variation and where missense variants are a common mechanism of disease.
Evidence considered
  • OncoKB gene-level context: ASXL1 is described as a tumor suppressor and epigenetic regulator inactivated in various cancer types; this does not establish both PP2 requirements for germline disease.
Still missing
  • A citable gene-level source quantifying benign missense variation and establishing missense as a common ASXL1 disease mechanism.
Sources
PP4 ACMG_2015Not assessed: no patient phenotype, family history, or specific disease diagnosis was supplied to judge highly specific phenotype evidence. Details ▾Hide ▴
Reasoning

The supplied case evidence does not document the patient's phenotype, family history, or a specific disease diagnosis. Without a phenotype or family-history description, specificity cannot be judged against a disease with a single genetic etiology.

Rule
PP4: Patient’s phenotype or family history is highly specific for a disease with a single genetic etiology.
Evidence considered
  • The case summary identifies ASXL1 p.Pro1062Ser but provides no patient phenotype, family history, or disease-specific clinical description.
Still missing
  • The patient's phenotype, family history, and suspected disease diagnosis are required.
BS3 ACMG_2015Not assessed: no validated in vitro or in vivo assay demonstrates preserved p.Pro1062Ser function or normal splicing with documented controls. Details ▾Hide ▴
Reasoning

No validated, reproducible in vitro or in vivo functional study of NM_015338.5:c.3184C>T (NP_056153.2:p.Pro1062Ser) demonstrating preserved protein function or normal splicing is present in the available case evidence. Computational predictions and database annotations do not satisfy the BS3 definition, and no assay controls, biological readout, or clinical-laboratory validation is documented; therefore BS3 cannot be assessed rather than being met or not_met.

Rule
Well-established in vitro or in vivo functional studies show no damaging effect on protein function or splicing.
Evidence considered
  • The consolidated case evidence contains no exact-variant functional assay report for NM_015338.5:c.3184C>T (NP_056153.2:p.Pro1062Ser).
  • Available computational predictions and database annotations are not direct functional studies and were not used to assign BS3.
Still missing
  • A validated, reproducible in vitro or in vivo assay directly testing p.Pro1062Ser is needed, with appropriate controls and a biologically relevant readout showing no damaging effect on protein function or splicing.
BS4 ACMG_2015Not assessed: no affected-family-member genotypes or phenotype-confirmed non-segregation observations are documented. Details ▾Hide ▴
Reasoning

No affected family members are documented as carrying or lacking the variant, and no pedigree or phenotype data are available. Lack of segregation therefore cannot be assessed; there is also no evidence permitting evaluation of the phenocopy caveat.

Rule
Lack of segregation in affected members of a family.
Evidence considered
  • The available case records contain no affected-relative genotypes, pedigree, or documented non-segregation observation.
  • No family evidence is available to assess the ACMG/AMP caveat concerning phenocopies or more than one pathogenic variant in a family.
Still missing
  • Affected family-member genotypes and phenotype-confirmed disease status.
  • Pedigree and segregation results sufficient to distinguish true non-segregation from phenocopy or a second pathogenic variant.
BP1 ACMG_2015Not assessed: loss-of-function biology is supported, but a citable source showing that ASXL1 disease variants are primarily truncating is absent. Details ▾Hide ▴
Reasoning

The available case evidence supports ASXL1 loss-of-function biology but does not provide a citable gene-level variant-spectrum source demonstrating that disease-causing ASXL1 variants are primarily truncating. The exact requirement for BP1 therefore cannot be confirmed from the supplied, registry-citable evidence.

Rule
Missense variant in a gene for which primarily truncating variants are known to cause disease.
Evidence considered
  • The case summary records ASXL1 loss-of-function mechanism support, but the supplied source registry does not contain a citable variant-spectrum reference establishing the word primarily for truncating variants.
Still missing
  • A citable gene-level disease-variant spectrum showing that primarily truncating ASXL1 variants are known to cause disease.
BP2 ACMG_2015Not assessed: no pathogenic partner variant or parental/offspring phase result establishes the required cis or trans configuration for BP2. Details ▾Hide ▴
Reasoning

BP2 requires observation in trans with a pathogenic variant for a fully penetrant dominant gene or disorder, or observation in cis with a pathogenic variant in any inheritance pattern. The available evidence contains no affected-proband observation, pathogenic partner variant, or parental/offspring phase result demonstrating cis or trans configuration, so BP2 cannot be assessed.

Rule
BP2: Observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.
Evidence considered
  • The case evidence does not report a pathogenic variant in cis or trans with NM_015338.5:c.3184C>T (NP_056153.2:p.(Pro1062Ser)).
  • The case evidence does not provide parental or offspring testing, haplotype data, or another validated phase determination.
Still missing
  • Documented pathogenic partner variant in the same individual and its classification.
  • Parental or offspring testing establishing whether NM_015338.5:c.3184C>T is in cis or trans with that pathogenic variant.
  • Clinical context confirming whether any trans observation is in a fully penetrant dominant ASXL1 disorder.
Not applicable · 5· recorded as not applicable Show reasons ▾Hide reasons ▴
PVS1 N/ANot applicable: PVS1 requires a null variant (nonsense, frameshift, canonical splice, start-loss or stop-loss), and this is a missense variant. Details ▾Hide ▴
Reasoning

PVS1 (ClinGen SVI PVS1 recommendations, PMC6185798, pvs1_generic_framework) applies only to null variant classes — nonsense, frameshift, canonical ±1/2 splice-consensus, translation-initiation-codon loss, and stop-loss variants — each expected to trigger nonsense-mediated decay or otherwise abolish normal protein function. NM_015338.5:c.3184C>T in ASXL1 is a missense substitution predicted to produce NP_056153.2:p.(Pro1062Ser). As a result, no null-variant mechanism (nonsense-mediated decay, truncation, or canonical splice disruption) is triggered by this variant class, so PVS1's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PVS1 for ASXL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_null_variant_class
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
PM3 N/ANot applicable: PM3 requires a recessive disorder, whereas the available ASXL1 germline disease context is dominant and no recessive inheritance is documented. Details ▾Hide ▴
Reasoning

PM3 is limited to recessive disorders and requires the variant to be detected in trans with a pathogenic variant, with phase established by parental or offspring testing. The available case evidence identifies ASXL1 germline disease in a dominant context and provides no recessive disorder context for this variant; therefore PM3 is not applicable.

Rule
PM3: For recessive disorders, detected in trans with a pathogenic variant ... Note: This requires testing of parents (or offspring) to determine phase.
Evidence considered
  • The case summary identifies ASXL1 germline disease context but does not document a recessive disorder, biallelic disease mechanism, or a pathogenic variant in trans.
  • No parent or offspring phase-testing result is available for this variant.
PM4 N/ANot applicable: PM4 requires a protein-length change, and this is a missense variant. Details ▾Hide ▴
Reasoning

PM4 (Richards et al. 2015, PMID:25741868) applies to protein length changes: in-frame insertions/deletions in a non-repetitive region, or stop-loss variants that extend the protein past the reference stop codon. NM_015338.5:c.3184C>T in ASXL1 is a missense substitution predicted to produce NP_056153.2:p.(Pro1062Ser). As a result, no change in protein length occurs, so there is nothing for this criterion to evaluate, so PM4's structural prerequisite is not met by this variant class. No VCEP criteria specification covers PM4 for ASXL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_stop_loss_or_nonrepeat_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP3 N/ANot applicable: BP3 requires an in-frame indel in a repeat region, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP3 (Richards et al. 2015, PMID:25741868) applies to in-frame insertions/deletions located in a repetitive region without a known function. NM_015338.5:c.3184C>T in ASXL1 is a missense substitution predicted to produce NP_056153.2:p.(Pro1062Ser). As a result, the variant does not alter protein length within a repeat region, so there is nothing for this criterion to evaluate, so BP3's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP3 for ASXL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_repeat_region_indel
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
pvs1_generic_framework ↗generic_acmg_combination_rules
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_015338.5:c.3184C>T in ASXL1 is a missense substitution predicted to produce NP_056153.2:p.(Pro1062Ser). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for ASXL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Identifiers

Gene
ASXL1
Transcript
NM_015338.5
Coding (HGVS c.)
NM_015338.5:c.3184C>T
Protein (HGVS p.)
NP_056153.2:p.(Pro1062Ser)
GRCh38
chr20:32435896 C>T
GRCh37
chr20:31023699 C>T
Location and type
Exon 13 · missense
ClinVar
4702721
COSMIC
COSV60106723

Gene diagram

Every interpreted variant in ASXL1, mapped onto the exon structure of NM_015338.5. Select a row to find it on the plot.

ASXL1NM_015338.5
Fetching transcript structure from UCSC…
gnomAD v4.1 26 / 1,614,170 alleles AF 1.61e-05 · 0 homozygotes · FAF 1.53e-05
gnomAD v2.1 3 / 251,416 alleles AF 1.19e-05 · 0 homozygotes · FAF 2.92e-06
gnomAD-Canada v1.0 Allele count data not recorded

By genetic ancestry

gnomAD v4.1

AF 1.6e-05 · 26 / 1,614,170 alleles · 0 hom · FAF 1.5e-05
European (non-Finnish)26 / 1,180,026 2.2e-05
0 alternate alleles recorded in 9 other groups: Remaining individuals, Admixed American, European (Finnish), Amish, East Asian, Middle Eastern, South Asian, Ashkenazi Jewish, African/African American.

gnomAD v2.1

AF 1.2e-05 · 3 / 251,416 alleles · 0 hom · FAF 2.9e-06
Remaining individuals1 / 6,134 0.00016
European (non-Finnish)2 / 113,700 1.8e-05
0 alternate alleles recorded in 6 other groups: African/African American, Admixed American, Ashkenazi Jewish, East Asian, European (Finnish), South Asian.

Statements

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.61073e-05; MAF= 0.00161%, 26/1614170 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 2.20334e-05; MAF= 0.00220%, 26/1180026 alleles, homozygotes = 0); grpmax FAF= 1.533e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.19324e-05; MAF= 0.00119%, 3/251416 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 0.000163026; MAF= 0.01630%, 1/6134 alleles, homozygotes = 0); grpmax FAF= 2.92e-06.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

SpliceAI and Pangolin

SpliceAI acceptor lossat +147 bp
0.000
SpliceAI acceptor gainat +488 bp
0.006
SpliceAI donor lossat -49 bp
0.003
SpliceAI donor gainat -198 bp
0.005
Pangolin splice lossmagnitude shown
-0.001
Pangolin splice gain
0.013

Other predictors

REVEL
0.018
BayesDel
-0.829

How the predictions were used

BP4 SupportingACMGMet at supporting: missense REVEL score 0.018 meets the BP4 threshold of <= 0.29. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, p.(Pro1062Ser), so the governing generic rule selects the REVEL path only; the SpliceAI score is not used for BP4. The REVEL score is 0.018, which is at or below the BP4 supporting cutoff of <= 0.29. Therefore BP4 is met at supporting strength. BayesDel is not used because no generic ACMG-strength calibration is established for it.

Rule
Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... REVEL (missense in-silico): BP4 (supporting): <= 0.29 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup: ASXL1 NM_015338.5:c.3184C>T, p.(Pro1062Ser), REVEL 0.018.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): BP4 supporting cutoff <= 0.29.
  • The variant is an exonic missense substitution; under the generic rule, REVEL is the sole applicable computational path, so the SpliceAI max delta 0.006 is not double-counted or substituted into BP4.
Sources
revel
PP3 ACMGNot met: missense REVEL score 0.018 is below the PP3 supporting threshold of >= 0.644. Details ▾Hide ▴
Reasoning

The variant is a missense substitution, p.(Pro1062Ser), so the governing generic rule selects the REVEL path only; SpliceAI and BayesDel are not used for PP3 in this situation. The REVEL score is 0.018, below the PP3 supporting cutoff of >= 0.644, so PP3 is not met.

Rule
Missense variant -> REVEL only. Its SpliceAI score says nothing about whether the amino-acid substitution is tolerated, so 'no predicted splice impact' is never BP4 support for a missense variant. ... REVEL (missense in-silico): PP3 (supporting): >= 0.644 — ClinGen SVI REVEL calibration (Pejaver et al. 2022, Am J Hum Genet) (PMID:36413997)
Evidence considered
  • Local REVEL lookup: ASXL1 NM_015338.5:c.3184C>T, p.(Pro1062Ser), REVEL 0.018.
  • ClinGen SVI REVEL calibration (Pejaver et al. 2022, PMID:36413997): PP3 supporting cutoff >= 0.644.
  • The variant is an exonic missense substitution; under the generic rule, REVEL is the sole applicable computational path and the SpliceAI score is not counted for PP3.
Sources
revel
BP7 N/ANot applicable: BP7 requires a synonymous variant, and this is a missense variant. Details ▾Hide ▴
Reasoning

BP7 (Richards et al. 2015, PMID:25741868) is defined for a synonymous (silent) variant for which splicing prediction algorithms predict no impact to the splice consensus sequence and the nucleotide is not highly conserved. NM_015338.5:c.3184C>T in ASXL1 is a missense substitution predicted to produce NP_056153.2:p.(Pro1062Ser). As a result, the encoded protein sequence is altered, so the criterion's silent-variant premise does not hold regardless of any splicing prediction, so BP7's structural prerequisite is not met by this variant class. No VCEP criteria specification covers BP7 for ASXL1, so the generic ACMG/AMP 2015 definition applies. This determination was made deterministically from the variant's consequence class, prior to LLM adjudication.

Rule
deterministic_prefilter: requires_synonymous
Evidence considered
  • Deterministic consequence classification: missense (prefetch.json normalized protein consequence)
  • VCEP criterion policy: absent
Sources
generic_acmg_combination_rules

Statement

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.018. BayesDel score = -0.82884.

0 paper records listed. No publication is explicitly linked to an applied criterion in the recorded metadata.

Screenshots represent source records captured during evidence collection. Select one to view the recorded source content.

All source links

Statements for reports

The evidence statements recorded by the interpretation pipeline. They have not been reinterpreted by the page.

gnomAD v4.1

This variant is present in gnomAD v4.1 (AF= 1.61073e-05; MAF= 0.00161%, 26/1614170 alleles, homozygotes = 0) and has highest observed frequency in the European (non-Finnish) population (AF= 2.20334e-05; MAF= 0.00220%, 26/1180026 alleles, homozygotes = 0); grpmax FAF= 1.533e-05.

gnomAD v2.1

This variant is present in gnomAD v2.1 (AF= 1.19324e-05; MAF= 0.00119%, 3/251416 alleles, homozygotes = 0) and has highest observed frequency in the Remaining individuals population (AF= 0.000163026; MAF= 0.01630%, 1/6134 alleles, homozygotes = 0); grpmax FAF= 2.92e-06.

gnomAD-Canada

Absent from gnomAD-Canada v1.0.

ClinVar

This variant has been reported in ClinVar as Uncertain significance (1 clinical laboratory). (ClinVarID = 4702721)

In silico

SpliceAI predicts no significant splice impact for this variant (max delta score = 0.01). REVEL score = 0.018. BayesDel score = -0.82884.

Functional

OncoKB did not identify variant-specific reviewed functional evidence for this variant; gene-level curated context is available for reviewer follow-up. ASXL1, a tumor suppressor and epigenetic regulator, is inactivated by mutation in various cancer types, most frequently in myeloid malignancies.

Somatic

This variant does not lie in a statistically significant hotspot. This variant has previously been reported in somatic cancers (COSMIC; COSV60106723, n = 2 times).

Cancer Hotspots

This variant does not lie in a statistically significant hotspot.